Welcome to our dedicated page for Lexicon Pharmaceuticals SEC filings (Ticker: LXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating clinical trial details, royalty milestones, or INPEFA® sales data inside Lexicon Pharmaceuticals’ 200-page reports can feel like its own research project. Biotech disclosures mix dense scientific tables with SEC jargon, and Lexicon Pharmaceuticals insider trading Form 4 transactions often arrive just as new study results hit the wire.
Stock Titan solves the puzzle. Our AI breaks each Lexicon Pharmaceuticals quarterly earnings report 10-Q filing, 8-K update, or proxy into concise, plain-English briefs. Need to spot dose-response outcomes in seconds? Curious how R&D spending shifted before Phase 3? You’ll find answers in our real-time dashboard, along with alerts for Lexicon Pharmaceuticals Form 4 insider transactions real-time. We cover every document type—10-K, 10-Q, 8-K, S-3, DEF 14A—linking them to natural questions investors ask, like “What does Lexicon disclose about LX9211’s safety profile?” or “How is executive compensation tied to FDA milestones?”.
Dive deeper with context you won’t get from EDGAR alone. Our summaries flag where the Lexicon Pharmaceuticals annual report 10-K simplified explains Genome5000™ costs, highlight each Lexicon Pharmaceuticals proxy statement executive compensation table, and translate risk-factor language into actionable insights. Follow Lexicon Pharmaceuticals earnings report filing analysis quarter over quarter, track Lexicon Pharmaceuticals executive stock transactions Form 4, and view every Lexicon Pharmaceuticals 8-K material events explained—all through one interface. If you’re serious about understanding Lexicon Pharmaceuticals SEC documents with AI-assisted clarity, this is your starting line.
Lexicon Pharmaceuticals (LXRX) has resolved its Nasdaq listing deficiency. On 23 Jul 2025 the company received written notice from Nasdaq Listing Qualifications confirming that LXRX’s common stock has maintained a closing bid price at or above the $1.00 threshold long enough to regain full compliance with Rule 5550(a)(2). As a result, the prior non-compliance matter is formally closed and no further action is required by the company.
The 8-K contains no financial performance data, operational updates, or strategic announcements; its sole purpose is to inform investors that the risk of delisting has been removed. Regaining compliance preserves LXRX’s access to the Nasdaq Global Select Market, supporting share liquidity and investor confidence.
Lexicon Pharmaceuticals, Inc. (LXRX) disclosed in an 8-K filing that on July 3, 2025 it received written notice from Nasdaq Listing Qualifications granting the company an additional 180-day grace period—until December 30, 2025—to regain compliance with the $1.00 minimum bid-price requirement for continued listing. To secure the extension, Lexicon applied to transfer its shares from the Nasdaq Global Select Market to the Nasdaq Capital Market; Nasdaq has approved the transfer, which will become effective at the opening of trading on July 7, 2025.
During the second compliance period, the company must deliver a closing bid price of at least $1.00 for 10 consecutive business days. Eligibility for the extension remains contingent on meeting all initial Capital Market listing standards—except the bid price—and providing written confirmation that Lexicon intends to cure the deficiency, which may include effecting a reverse stock split if necessary.
The notice prevents an immediate delisting but underlines the ongoing risk that LXRX shares could be removed from Nasdaq if compliance is not restored by year-end. Investors should monitor management’s plans—particularly any potential reverse split—and the stock’s trading performance over the coming months.
FAQ
What is the current stock price of Lexicon Pharmaceuticals (LXRX)?
What is the market cap of Lexicon Pharmaceuticals (LXRX)?
